Article · 7 Oct 2025
Research articlePublished 3 Mar 2022
A Dialectological Pharmacovigilance Study of the Rational Pharmacotherapeutic Appraisal of the Combination Therapies of 50 mg or 75 mg Remogliflozin with 500 mg Metformin, and an Anti-Diabetic Tertiary Medical Healthcare Patient Satisfaction Evaluation: A Research Series, in Evidence-Based Medicine
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
INTRODUCTION Remogliflozin, a selective insulin independent sodium glucose co - transporter subtype 2 (SGLT2) inhibitor, inhibits reabsorption of renal glucose, lowers blood sugar, and causes glucosuria, in type II diabetes mellitus patients. Metformin, as a combination anti-diabetic drug, lowers serum glucose levels; by the activation of 5’ Adenosine Monophosphate (AMP) activated protein kinase. OBJECTIVES The objective of this Evidence-Based Medicine research series was the rational pharmacotherapeutic appraisal of the diabetological pharmacovigilance of the combination therapies of 50 mg or 75 mg remogliflozin with 500 mg metformin among type II diabetics, in tertiary care medical college hospitals, along global pharmacoepidemiology, and an anti - diabetic tertiary medical healthcare patient satisfaction evaluation. METHODS 125 new early moderate grade type II diabetes mellitus patients were prescribed oral metformin 500 mg once daily for 30 days. Then, 100 diabetics uncontrolled with metformin monotherapy, were prescribed oral 50 mg remogliflozin with 500 mg metformin once daily, for 15 days; who were subsequently prescribed oral 75 mg remogliflozin with 500 mg metformin once daily for 15 days. The safety assessment, along with blood sugar and HbA1c levels and urine routine examination, on day 0, day 30, day 46, day 60, and further follow - up, were recorded and statistically analysed. An anti - diabetic tertiary medical healthcare patient satisfaction evaluation was also performed by patient response to different attributes of anti-diabetic treatment. RESULTS The adverse effects with the combination therapy of 50 mg remogliflozin with metformin and the combination therapy of 75 mg remogliflozin with metformin were statistically non - significant; hence both were safe and tolerable. All the patients were satisfied with each anti-diabetic medical healthcare attribute. CONCLUSION The combination therapy of 50 mg remogliflozin and metformin as well as the combination therapy of 75 mg remogliflozin and metformin were safe and tolerable. There was ample anti - diabetic medical healthcare satisfaction.
Keywords
Subjects
Nursing & HealthcareAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Evidence-Based Medicine and Healthcare.
Article · 28 Jul 2025
Association between Admission Blood Pressure, Stroke Severity and Early Outcome in Thrombolysed Ischemic Stroke Patients: A Single Centre Experience from Northeast India
Article · 28 Mar 2025
Isolated Paralysis of Extensor Indicis and EDC Tendon of Index Finger Following Thompsonandrsquo;s Approach to Proximal Radius-Case Report
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Evidence-Based Medicine and Healthcare
- SubjectNursing & Healthcare
- BylineArticles whose byline prints “Moumita Hazra”